结直肠癌是第三大最常见的癌症,在癌症相关死亡病例中排名第二。综合疗法会产生许多不良影响,让病人放弃。近年来已经研究了纳米技术以规避局限性。由聚合物组成的组,脂质,和无机纳米粒子是最有目的的。因此,这项工作的目的是提供有关纳米系统如何改善结直肠癌化疗治疗的信息。因此,在“LILACS”等期刊中搜索,执行了“SciELO”和“PubMed/Medline”,在应用搜索引擎“纳米粒子”时发现了25,000篇文章,\"\"结直肠癌,“恶性肿瘤,“和”化疗。“在包含和排除因素之后,剩下24条,这些都被用作这次综合审查的基础。结果表明,不管矩阵的选择,纳米颗粒显示活性物质的生物利用度增加,半衰期增加了13倍,修改版本,以及肿瘤大小的显著减小,细胞活力比测试的免费药物低20%,在不同的结直肠癌细胞系中,例如HCT-116、HT-29和CaCo-2。然而,需要进行更多的体内和临床研究,不管它的矩阵是什么,旨在提高患者的安全性和制剂的稳定性,以及其药代动力学和药效学的详细指标的知识,寻求避免对受体生物体的进一步损害。
Colorectal cancer is the third most common cancer and the second in cases of cancer-related death. Polytherapy generates many adverse effects, leading the patient to give up. Nanotechnology has been studied in recent years to circumvent limitations. Groups composed of polymeric, lipid, and inorganic nanoparticles are the most purpose. Thus, the objective of this work is to bring information on how nanosystems can improve the chemotherapeutic treatment for colorectal cancer. Therefore, a search in journals such as \"LILACS\", \"SciELO\" and \"PubMed/Medline\" was performed, resulting in 25,000 articles found when applied the search engines \"nanoparticle,\" \"colorectal cancer,\" \"malignant neoplasms,\" and \"chemotherapy.\" After inclusion and exclusion factors, 24 articles remained, which were used as the basis for this integrative
review. The results reveal that, regardless of the choice of matrix, nanoparticles showed an increase in bioavailability of the active, increasing the half-life by up to 13 times, modified release, as well as a significant reduction in tumor size, with cell viability up to 20% lower than the free drug tested, in different colorectal cancer cell lines, such as HCT-116, HT-29, and CaCo-2. However, more in vivo and clinical studies need to be performed, regardless of the formulation of its matrix, aiming at a higher rate of safety for patients and stability of the formulations, as well as knowledge of detailed indices of its pharmacokinetics and pharmacodynamics, seeking to avoid further damage to the recipient organism.